Bavarian Nordic A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bavarian Nordic A/S
The firm anticipates a late-stage study of MVA-BN RSV in the first half of 2022
Coronavirus Notebook: EMA OKs Roche's Tocilizumab For Severe COVID-19, Bavarian Nordic Reports ‘Positive’ Booster Results
The European Commission is to replace its COVID-19 vaccine export authorization system with a monitoring scheme, and the European Medicines Agency has confirmed the risk of myocarditis and pericarditis with the mRNA vaccines. The WHO and other bodies have called for better vaccine donation practices in Africa.
ACIP working group proposal for all adults was altered to include an upper age limit for universal hepatitis B vaccination.
Solid Phase II data for Bavarian Nordic’s investigational vaccine MVA-BN RSV showed falls in both symptoms and viral load of respiratory syncytial virus in the challenge trial’s adult participants, boosting prospects for a Phase III trial - and for finding a commercial partner.
- Large Molecule